Shionogi and Ferrer Conclude a Contract for the Promotion in Spain of ▼ RIZMOIC® (naldemedine), a Therapeutic Agent for Opioid-Induced Constipation
SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Ferrer (Headquarters: Barcelona, Spain; CEO: Mario Rovirosa) announced today that Shionogi and Ferrer concluded an exclusive promotion agreement for RIZMOIC® (naldemedine) in Spain for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005901/en/
Shionogi has built a strong heritage in research-based medicine. The company’s research and development efforts target pain/central nervous system as one of its priority therapeutic areas of interest. The company constantly strives to improve the quality of life of patients who suffer from pain or side effects of analgesics by bringing forth innovative drugs.
Ferrer’s activity covers the entire health spectrum in Spain and many other countries worldwide, including expertise in pain management by opioid treatment. The company’s strong commitment to improving the wellbeing of society and its integrated model spanning from R&D through to distribution, ensures their range of products offer real benefits in rapidly changing environments.
Dr. John Keller, Chief Executive Officer of Shionogi B.V., the subsidiary of Shionogi in Europe, said “We are delighted to collaborate with Ferrer in Spain. This collaboration marks an additional key milestone for the launch of RIZMOIC® in Europe. Ferrer is a company that is well trusted and highly respected, with not only an established commercial structure that is ideal for the introduction of RIZMOIC ® , but also a deep knowledge of pain management that augments and aligns with our own.”
Ferrer’s Chief Executive Officer, Mario Rovirosa, commented, “We are pleased to partner with Shionogi on this promising treatment which has the potential to make a real impact on the lives of many people currently suffering from OIC across Spain. This partnership allows us to introduce an innovative treatment to reduce the burden in this disease area. Moreover, this agreement complements our expertise in the field of pain relief”.
On February 18, 2019, the European Commission (EC) granted the Marketing Authorization (MA) for RIZMOIC® for the treatment of OIC in adult patients who have previously been treated with a laxative.1,2 RIZMOIC® is planned to be launched in Spain in 2020. RIZMOIC® was launched under the brand name Symproic® in Japan in June 2017, and in the United States in October 2017.3-5
End
About Opioid‐induced Constipation
Constipation is one of the
most commonly reported side effects associated with opioid treatment,
particularly among patients with chronic non-cancer pain and patients
with cancer pain.6 OIC is a result of increased fluid
absorption and reduced gastro-intestinal (GI) motility due to mu-opioid
receptor binding in the GI tract. OIC is defined as a change in bowel
habits that is characterized by any of the following after initiating
opioid therapy: reduced bowel movement frequency, development or
worsening of straining to pass bowel movements, a sense of incomplete
rectal evacuation, or harder stool consistency.7 In patients
receiving opioid therapy for chronic non-cancer pain, the prevalence of
OIC ranges from approximately 40-60 percent.8
About RIZMOIC
®
RIZMOIC® (naldemedine)
is indicated for the treatment of opioid‐induced constipation (OIC) in
adult patients who have previously been treated with a laxative. RIZMOIC®
is a peripherally acting mu-opioid receptor antagonist (PAMORA) that has
been developed by Shionogi as a once‐daily treatment of OIC. The
efficacy and safety of naldemedine have been evaluated in randomized,
double-blinded, placebo-controlled studies in adult patients with OIC
who have chronic non-cancer pain or who have cancer pain.9-13
RIZMOIC® is expected to be a new treatment option that can
improve the quality of life significantly in patients with OIC in pain
management with opioid analgesics.
▼ This medicinal product is subject to additional monitoring. Detailed information on this medicinal product is available on the website of the European Medicines Agency www.ema.europa.eu.
About Shionogi
Shionogi & Co., Ltd. (“Shionogi”) is a
Japanese major research‐driven pharmaceutical company dedicated to
bringing benefits to patients based on its corporate philosophy of
“supplying the best possible medicine to protect the health and
wellbeing of the patients we serve.” The company currently markets
products in several therapeutic areas including anti-infectives, pain,
CNS disorders, gynaecology and gastroenterology. Shionogi’s research and
development currently target two therapeutic areas: infectious diseases
and pain/CNS disorders. For more information on Shionogi, please visit http://www.shionogi.co.jp/en/.
Shionogi B.V. is the European subsidiary of Shionogi & Co., Ltd. based
in Amsterdam, Netherlands. For more information on Shionogi B.V. please
visit www.shionogi.eu.
About Ferrer
Founded in Spain in 1959, Ferrer is a
privately-held international pharmaceutical company headquartered in
Barcelona. It is active throughout the full value chain, from R&D to
international distribution. It is present in more than 110 countries,
with 19 international affiliates. Ferrer is active in the
pharmaceutical, health, fine chemical and food sectors, key areas for
contributing to people’s health and wellbeing. Since the beginning,
Ferrer has been committed to the research and development of innovative
medicinal products and to maintain a solid industrial structure.
Ferrer’s activity across the entire healthcare spectrum includes
prescription drugs, hospital products and diagnostics. For more
information on Ferrer, please visit www.ferrer.com.
Forward Looking Statement
This announcement contains
forward-looking statements. These statements are based on expectations
in light of the information currently available, assumptions that are
subject to risks and uncertainties which could cause actual results to
differ materially from these statements. Risks and uncertainties include
general domestic and international economic conditions such as general
industry and market conditions, and changes of interest rate and
currency exchange rate. These risks and uncertainties particularly apply
with respect to product related forward‐looking statements.
Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward‐looking statements whether as a result of new information, future events or otherwise.
References
1.
Release on February 22, 2019
Shionogi announces European Union
Marketing Authorisation for RIZMOIC® (naldemedine) for the
treatment of opioid-induced constipation in adults previously treated
with a laxative
2. SmPC, RIZMOIC®, Shionogi,
Feb 2019. [online] Available at:
https://www.ema.europa.eu/documents/product-information/rizmoic-epar-product-information_en.pdf
[Accessed 20 May 2019].
3.
Release on June 7, 2017
Opioid-Induced Constipation therapeutic
agent ‘Symproic® (naldemedine) Tablets 0.2mg’ launched in
Japan
4.
Release on October 12, 2017
Shionogi Inc. and Purdue Pharma
L.P. Announce U.S. Availability of Symproic® (naldemedine)
for the Treatment of Opioid-Induced Constipation in Adults with Chronic
Non-Cancer Pain
5.
Release on April 11, 2019
Shionogi Announces Licensing of
Symproic® (naldemedine) to BioDelivery Sciences International
Inc.
6. Sehgal N, et al. Chronic pain treatment with
opioid analgesics benefits versus harms of long-term therapy. Expert Rev
Neurother. 2013; 13:1201-1220.
7. Camilleri M, et al.
Emerging treatments in neurogastroenterology: a multidisciplinary
working group consensus statement on opioid-induced constipation.
Neurogastroenterol Motil. 2014;26: 1386-1395.
8. Coyne
E, et al. Opioid-Induced constipation among patients with chronic
Noncancer pain in the United States, Canada, Germany and the United
Kingdom: Laxative use, response and symptom burden over time. Pain.
2015; 16:1551–1565.
9. Hale M, et al. Naldemedine versus
placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two
multicentre, phase3, double-blind, randomised, parallel-group trials.
Lancet Gastroenterol Hepatol. 2017. Published online May 30, 2017.
10.
Webster L, et al. Long term use of naldemedine in the treatment of
opioid-induced constipation in patients with chronic noncancer pain: a
randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018.
Published online February 6 2018.
11. Bowers B, et al.
The evolving role of long-term pharmacotherapy for opioid-induced
constipation in patients being treated for noncancer pain. Jour Pharm
Practice. 2017.
12. Katakami N, et al. Randomized phase
III and extension studies: efficacy and impacts on quality of life of
naldemedine in subjects with opioid-induced constipation and cancer. Ann
Oncol. 2018. Published online Apr 18, 2018.
13. Satomi
E, et al. Efficacy and tolerability of naldemedine in patient with
cancer and opioid induced constipation: A pooled subgroup analysis of 2
randomised placebo-controlled studies. Ann Oncol. 2018. 29 (suppl 8).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005901/en/
Contact information
Shionogi Europe
Dr. Mark Hill, Shionogi, mark.hill@shionogi.eu
Mirjam
Korn, Shionogi, mirjam.korn@shionogi.eu
Shionogi & Co., Ltd.
Corporate Communications Department
Telephone:
+81-6-6209-7885
Ferrer BD and Licensing
Ana Aliaga, Ferrer, aaliaga@ferrer.com
Ferrer Corporate Communications
Gorka Ortiz de Zárate,
Ferrer, gortizdezarate@ferrer.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo